Nucala 100 MG/ML auto-injectorml
Ended Awarded
- Contract number
- SPE2DB25FZK64
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $22,715
Award facts
- Contract value 100% obligated
- $22,714.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $22,714.80 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nucala 100 mg/ml auto-injectors. The contract was awarded on July 24, 2025, with an ultimate completion date of July 25, 2025, and carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's existing single-award Indefinite Delivery Contract with the DLA under the SPE2DB program, a $500 million vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products to support military health facilities worldwide.
Nucala (mepolizumab) is a biologic medication used primarily in the treatment of severe asthma and other eosinophilic conditions. DMS Pharmaceutical Group has established itself as a critical supplier in the federal pharmaceutical supply chain, consistently securing delivery orders from the DLA for prescription medications, biologics, and medical consumables supporting Department of Defense healthcare facilities. The company's status as a woman-owned small business has enabled it to compete effectively in federal procurement markets, and its extensive contract portfolio demonstrates proven capability in distributing specialized pharmaceutical products to military medical systems across the United States.
Quick answers
Who was awarded contract SPE2DB25FZK64?
SPE2DB25FZK64 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on July 24, 2025.
How much is contract SPE2DB25FZK64 worth?
The government has obligated $22,715 on SPE2DB25FZK64.
Is contract SPE2DB25FZK64 an order under another contract?
Yes. SPE2DB25FZK64 is a delivery order under SPE2DB20D9329, an indefinite delivery contract.
Was contract SPE2DB25FZK64 competed?
The extent of competition for SPE2DB25FZK64 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award